Revolutionary Therapy from the Microbiome: Mbiomics Leads the Way
Mbiomics, a groundbreaking biotech startup based in Munich, is on a mission to fundamentally change the treatment of immune-associated and neurodegenerative diseases. The company is spearheading a new era in microbiome-based therapies, setting itself apart with its innovative TechBio platform.
Unlike most other companies, Mbiomics offers an end-to-end platform for designing and scalable production of complex microbiome consortia, composed of over 100 bacterial strains. This approach, which leverages advanced AI to optimize physical and mental health management, represents a highly precise, customizable, and scalable therapeutic strategy compared to traditional one-size-fits-all microbiome therapies.
The TechBio platform distinguishes itself by enabling the creation of tailor-made medications targeted against complex diseases such as cancer, autoimmune, and neurodegenerative disorders. The combination of a broad spectrum of bacterial strains in custom formulations, integration of artificial intelligence for enhanced precision in therapy design and optimization, and a focus on both mental and physical health management, all contribute to its unique position in the microbiome space.
Moreover, the platform’s design aims for scalability through AI-driven and modular therapy development, potentially enabling faster development cycles and wider accessibility. This scalability is crucial for addressing the complexities of diseases like cancer, autoimmune, and neurodegenerative disorders.
Mbiomics' founders, Johannes B. Woehrstein and Heinrich Grabmayr, are physicists and experienced biotech entrepreneurs. The integration of a diverse team of scientists, technologists, and clinical developers has been a significant challenge for Mbiomics. However, excellent communication and project management skills are crucial for managing such a diverse team and multiple projects.
Munich, with its proximity to excellent research institutions, dense life science community, and access to talent and funding programs, is an ideal location for Mbiomics. The company is planning to enter clinical trials for a pilot product in cancer therapy within a year. In five years, Mbiomics aims to have clinical projects in multiple disease areas, including immuno-oncology, neurodegenerative, inflammatory, and autoimmune diseases.
Mbiomics' long-term vision is to become a champion and pioneer in microbiome-based therapies. The company is seeking more specialized investors in deeptech and life sciences who have the patience this industry demands, as developing and commercializing a novel therapeutic modality takes time. Despite the challenges, Mbiomics is working at maximum speed to build a solid foundation for this revolutionary approach to disease treatment.
[1] Mbiomics. (n.d.). About Mbiomics. Retrieved from https://www.mbiomics.com/about
[2] Mbiomics. (n.d.). TechBio Platform. Retrieved from https://www.mbiomics.com/techbio-platform
- Mbiomics, with a focus on revolutionizing the treatment of complex medical conditions like cancer, autoimmune, and neurodegenerative disorders, is leveraging science and technology to develop a precision-driven approach in health and wellness, elevating their position in the microbiome space through their TechBio platform.
- In the pursuit of becoming a pioneer in microbiome-based therapies, Mbiomics is seeking specialized investors in deeptech and life sciences who appreciate the industry's unique demands and are willing to support their long-term vision, as the development and commercialization of novel therapeutic modalities require patience and considerable effort.
